Search

Home > New FDA Approvals > 030 - FDA grants marketing authorization of NSS bridge for opioid withdrawal; FDA approves Mepsevil for mucopolysaccharidosis type VII; Faslodex plus abemaciclib for advanced breast cancer; Fasenra (benralizumab) receives US FDA approval for severe eosino


	Podcast:		New FDA Approvals
	Episode:		030 - FDA grants marketing authorization of NSS bridge for opioid withdrawal; FDA approves Mepsevil for mucopolysaccharidosis type VII; Faslodex plus abemaciclib for advanced breast cancer; Fasenra (benralizumab) receives US FDA approval for severe eosino
	Category:		Science & Medicine
	Duration:		00:12:20
	Publish Date:		2017-11-16 07:00:00
	Description:		November 16, 2017 0:25 FDA grants marketing authorization of the first device for use in helping to reduce the symptoms of opioid withdrawal https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585271.htm 2:42 FDA approves Mepsevil to treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. FDA approves treatment for rare genetic enzyme disorder 5:32 Faslodex (fulvestrant) receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib-15112017.html 6:52 Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html 9:12 FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585347.htm If we can help with any medical writing, please reach out to us at info@nascentmc.com Our US-based company, Nascent Medical, LLC, has a team of over 100 PhD-/MD-level writers who can write about any medical, scientific or technical topic. We charge a flat rate and provide an upfront estimate. Our turn around times can be as short as 1 to 2 days depending on the length of the project, and we don't charge extra for our speediness. Have you updated your blog or posted any press releases lately? That's a small project that some clients like to test us out with to start. We do the following types of writing, including but not limited to: -Video and virtual reality script writing -eLearning scripts -Medical education -Webinar slide creation -Manuscripts -Slidesets -Manuscripts -Press releases -Blog posts
	Total Play:		0